These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 22510390

  • 1. Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry.
    Egerer G, Reichert D, Pletz MW, Kaskel P, Krobot KJ, Maertens J.
    Eur J Med Res; 2012 Apr 17; 17(1):7. PubMed ID: 22510390
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study.
    Winkler M, Pratschke J, Schulz U, Zheng S, Zhang M, Li W, Lu M, Sgarabotto D, Sganga G, Kaskel P, Chandwani S, Ma L, Petrovic J, Shivaprakash M.
    Transpl Infect Dis; 2010 Jun 17; 12(3):230-7. PubMed ID: 20070619
    [Abstract] [Full Text] [Related]

  • 6. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
    Raad II, Zakhem AE, Helou GE, Jiang Y, Kontoyiannis DP, Hachem R.
    Int J Antimicrob Agents; 2015 Mar 17; 45(3):283-8. PubMed ID: 25455847
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of caspofungin for the treatment of invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease.
    Li S, Li Z, Wang P, Zhan Y, Xie J, Ye F.
    J Int Med Res; 2024 Mar 17; 52(3):3000605241237878. PubMed ID: 38530040
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.
    Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A, Giagounidis A, Marchetti O, Martino R, Meert L, Paesmans M, Ameye L, Shivaprakash M, Ullmann AJ, Maertens J, Infectious Disease Group of the EORTC.
    J Antimicrob Chemother; 2009 Dec 17; 64(6):1274-81. PubMed ID: 19841031
    [Abstract] [Full Text] [Related]

  • 11. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
    Zaoutis TE, Jafri HS, Huang LM, Locatelli F, Barzilai A, Ebell W, Steinbach WJ, Bradley J, Lieberman JM, Hsiao CC, Seibel N, Laws HJ, Gamba M, Petrecz M, Taylor AF, Strohmaier KM, Chow JW, Kartsonis NA, Ngai AL.
    Pediatrics; 2009 Mar 17; 123(3):877-84. PubMed ID: 19255017
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
    Betts R, Glasmacher A, Maertens J, Maschmeyer G, Vazquez JA, Teppler H, Taylor A, Lupinacci R, Sable C, Kartsonis N.
    Cancer; 2006 Jan 15; 106(2):466-73. PubMed ID: 16353208
    [Abstract] [Full Text] [Related]

  • 13. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.
    Herbrecht R, Maertens J, Baila L, Aoun M, Heinz W, Martino R, Schwartz S, Ullmann AJ, Meert L, Paesmans M, Marchetti O, Akan H, Ameye L, Shivaprakash M, Viscoli C.
    Bone Marrow Transplant; 2010 Jul 15; 45(7):1227-33. PubMed ID: 20062093
    [Abstract] [Full Text] [Related]

  • 14. Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections.
    Heinz WJ, Buchheidt D, Ullmann AJ.
    Mycoses; 2016 Aug 15; 59(8):480-93. PubMed ID: 27324802
    [Abstract] [Full Text] [Related]

  • 15. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.
    Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH, Killar J, Taylor A, Kartsonis N, Patterson TF, Aoun M, Caillot D, Sable C, Caspofungin Combination Therapy Study Group.
    Cancer; 2006 Dec 15; 107(12):2888-97. PubMed ID: 17103444
    [Abstract] [Full Text] [Related]

  • 16. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
    Thomas A, Korb V, Guillemain R, Caruba T, Boussaud V, Billaud E, Prognon P, Begué D, Sabatier B.
    J Clin Pharm Ther; 2010 Feb 15; 35(1):49-53. PubMed ID: 20175811
    [Abstract] [Full Text] [Related]

  • 17. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia.
    Lafaurie M, Lapalu J, Raffoux E, Breton B, Lacroix C, Socié G, Porcher R, Ribaud P, Touratier S, Molina JM.
    Clin Microbiol Infect; 2010 Aug 15; 16(8):1191-6. PubMed ID: 19735276
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
    Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ, Caspofungin Salvage Aspergillosis Study Group.
    Clin Infect Dis; 2004 Dec 01; 39(11):1563-71. PubMed ID: 15578352
    [Abstract] [Full Text] [Related]

  • 19. Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study).
    Jarque I, Tormo M, Bello JL, Rovira M, Batlle M, Julià A, Tabares S, Rivas C, Fernández-Sevilla A, García-Boyero R, Debén G, González-Campos J, Capote FJ, Sanz MA, Spanish Pethema Group.
    Med Mycol; 2013 Feb 01; 51(2):150-4. PubMed ID: 22712457
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.